Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure

被引：0

作者：

Kentaro Ejiri

Toru Miyoshi

Hajime Kihara

Yoshiki Hata

Toshihiko Nagano

Atsushi Takaishi

Hironobu Toda

Seiji Namba

Yoichi Nakamura

Satoshi Akagi

Satoru Sakuragi

Taro Minagawa

Yusuke Kawai

Nobuhiro Nishii

Soichiro Fuke

Masaki Yoshikawa

Kazufumi Nakamura

Hiroshi Ito

机构：

[1] Okayama University Graduate School of Medicine,Department of Cardiovascular Medicine

[2] Dentistry and Pharmaceutical Sciences,Department of Internal Medicine

[3] Tamano City Hospital,Department of Internal Medicine

[4] Kihara Cardiovascular Clinic,Department of Cardiology

[5] Minamino Cardiovascular Hospital,Department of Internal Medicine

[6] Iwasa Hospital,Department of Cardiology

[7] Mitoyo General Hospital,Department of Internal Medicine

[8] Okayama East Neurosurgery Hospital,Department of Cardiology

[9] Okayama Rosai Hospital,Department of Cardiovascular Medicine

[10] Specified Clinic of Soyokaze Cardiovascular Medicine and Diabetes Care,Department of Internal Medicine

[11] Akaiwa Medical Association Hospital,Department of Cardiovascular Medicine

[12] Iwakuni Clinical Center,Department of Internal Medicine

[13] Minagawa Cardiovascular Clinic,Department of Cardiovascular Medicine

[14] Okayama City Hospital,Department of Internal Medicine

[15] Yoshinaga Hospital,Department of Cardiovascular Medicine

[16] Japanese Red Cross Okayama Hospital,Department of Cardiology

[17] Fukuyama City Hospital,undefined

[18] Okayama University Graduate School of Medicine,undefined

[19] Dentistry and Pharmaceutical Sciences,undefined

[20] Tamano City Hospital,undefined

[21] Kihara Cardiovascular Clinic,undefined

[22] Minamino Cardiovascular Hospital,undefined

[23] Iwasa Hospital,undefined

[24] Mitoyo General Hospital,undefined

[25] Okayama East Neurosurgery Hospital,undefined

[26] Okayama Rosai Hospital,undefined

[27] Specified Clinic of Soyokaze Cardiovascular Medicine and Diabetes Care,undefined

[28] Akaiwa Medical Association Hospital,undefined

[29] Iwakuni Clinical Center,undefined

[30] Minagawa Cardiovascular Clinic,undefined

[31] Okayama City Hospital,undefined

[32] Yoshinaga Hospital,undefined

[33] Japanese Red Cross Okayama Hospital,undefined

[34] Fukuyama City Hospital,undefined

[35] Imai Heart Clinic,undefined

[36] Gotoh Clinic,undefined

[37] Asahi University Hospital,undefined

[38] Gifu Prefectural General Medical Center,undefined

[39] Gifu Seiryu Hospital,undefined

来源：

Scientific Reports | / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular events in patients with heart failure irrespective of diabetes status. In this prespecified sub-analysis of randomised-controlled trial, we investigated the efficacy of luseogliflozin (2.5 mg daily), a sodium–glucose cotransporter 2 inhibitor, with that of voglibose (0.6 mg daily), an alpha-glucosidase inhibitor, on high-risk lipid profile and inflammatory markers in patients with type-2 diabetes and heart failure. Among the 157 patients studied, there were no significant differences in the mean malondialdehyde LDL or small-dense LDL cholesterol levels between the luseogliflozin and voglibose groups (percent change: 0.2% vs. − 0.6%, p = 0.93; − 1.7% vs. − 8.6%, p = 0.21) after 12 weeks in comparison to levels at the baseline. No significant difference was observed between the two groups in the adiponectin and high-sensitivity C-reactive protein levels after 12 weeks compared to the baseline levels (percent change, − 1.6% vs. − 4.0% and 22.5% vs. 10.0%; p = 0.52 and p = 0.55, respectively). In conclusion, in patients with type-2 diabetes and heart failure, compared to voglibose, luseogliflozin did not significantly improve the high-risk lipoprotein profile including malondialdehyde LDL and small-dense LDL cholesterol or the levels of inflammatory markers, including adiponectin and high-sensitivity C-reactive protein.

引用

共 59 条

[1] Zinman B(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N. Engl. J. Med. 373 2117-2128
[2] Neal B(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N. Engl. J. Med. 377 644-657
[3] Wiviott SD(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N. Engl. J. Med. 380 347-357
[4] Cannon CP(2020)Cardiovascular outcomes with ertugliflozin in type 2 diabetes N. Engl. J. Med. 383 1425-1435
[5] McMurray JJV(2019)Dapagliflozin in patients with heart failure and reduced ejection fraction N. Engl. J. Med. 381 1995-2008
[6] Packer M(2020)Cardiovascular and renal outcomes with empagliflozin in heart failure N. Engl. J. Med. 383 1413-1424
[7] Heerspink HJ(2016)Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications Circulation 134 752-772
[8] Perkins BA(2019)Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects Circulation 139 1985-1987
[9] Fitchett DH(2016)No need to sugarcoat the message: Is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? Am. J. Kidney Dis. 68 349-352
[10] Husain M(2014)The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovasc. Diabetol. 13 28-259

← 1 2 3 4 5 6 →